Latest Capital Raises News

Identitii Limited reported a modest 4% revenue increase to $777,542 for FY25, yet its net loss expanded by 8% to $3.82 million, driven by lower investment gains. The company strengthened its cash position through successful capital raising and ongoing cost reductions.

Pure Hydrogen Corporation has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed market activity for the energy company.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Activeport Group Ltd reported a significant $15.7 million net loss for FY25, driven by a $10.9 million goodwill impairment, as it pivots towards recurring software revenue. The company plans a $2.5 million rights issue to support this transition amid ongoing financial challenges.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.